宠物癌症药物市场－全球产业规模、份额、趋势、机会及预测（依治疗方法、动物种类、癌症种类、地区及竞争格局划分，2021-2031年）

全球宠物癌症药物市场预计将从 2025 年的 4.6769 亿美元大幅成长至 2031 年的 8.1641 亿美元，复合年增长率为 9.73%。

此细分市场涵盖专门针对伴侣动物恶性肿瘤开发的药物和生物製药，包括免疫疗法、化疗和分子标靶药物。市场成长的主要驱动因素是宠物预期寿命的延长（导致癌症发病率老龄化增长而增加）以及人与动物之间日益紧密的联繫，如今饲主对兽医肿瘤科的医疗服务水平提出了与人类同等的要求。此外，诊断准确性的提高使得肿瘤能够更早被发现，从而即时需要超越基本安宁疗护的有效治疗方法。

市场扩张的一大障碍是先进肿瘤治疗的高昂费用，这往往限制了没有保险的宠物饲主获得治疗的机会。儘管存在这些经济障碍，兽医保健的总投入仍在持续成长，凸显了饲主对宠物健康的高度重视。根据美国宠物用品协会 (APPA) 预测，到 2024 年，美国兽医保健和产品销售额预计将达到 398 亿美元。如此巨大的支出表明，儘管先进治疗方法的高昂费用带来了挑战，但仍有强大的经济基础来支持新型癌症治疗方法的研发和商业化。

市场驱动因素

全球宠物癌症治疗市场正因新型标靶治疗和免疫疗法的研发而发生变革，标誌着治疗方式正从传统的特异性化疗转向精准治疗。兽医肿瘤学正日益采用精准医疗方法，利用单株抗体和自体疫苗来改善临床疗效并最大限度地减少副作用。这种以疗效为导向的创新趋势得益于免疫疗法的最新成功，为希望延长宠物寿命的饲主提供了强有力的证据。例如，2025年2月，Torigen Pharmaceuticals公司报告称，其针对转移性血管肉瘤犬的标靶免疫疗法，与单纯手术相比，可使犬隻的整体存活期延长3.5倍。这些成果正在加速这些先进药物的商业性化应用。

同时，宠物健康保险覆盖范围的扩大也带来了重要的经济成长，降低了以往阻碍宠物获得昂贵肿瘤治疗的经济门槛。随着保险覆盖率的提高，饲主更容易负担昂贵的治疗方案，从而将潜在需求转化为实际的市场收入。 2025年4月，北美宠物健康保险协会（NAPHIA）报告称，到2024年底，北美投保宠物总数将达到703万隻，同比增长12.2%。这一不断扩大的经济安全网正鼓励製药公司增加对研发管线的投资。例如，2025年5月，礼来动物保健公司（Elanco Animal Health）将2025财年的创新收入目标从6.6亿美元上调至7.4亿美元，凸显了将新一代兽药推向市场的巨大商业性潜力。

市场挑战

先进的肿瘤治疗方法费用高昂，是限制全球宠物癌症治疗市场成长的主要障碍。新兴的标靶治疗和化疗虽然能改善临床疗效，但其高昂的价格往往令许多宠物主人望而却步。由于缺乏广泛的第三方报销，经济负担几乎完全落在饲主饲主身上，迫使许多人放弃根治性治疗，转而选择费用较低的安宁疗护。这种经济压力限制了药物研发者的潜在市场规模，并降低了新药研发的投资报酬率。

这项限制也源自于宠物保险普及率低，导致大多数饲主面临意外高医疗费用的风险。根据北美宠物健康保险协会（NAPHIA）预测，到2024年，美国投保宠物总数将达到640万隻，市场渗透率仅3.9%。由于大多数伴侣动物没有保险，高附加价值疗法的商业性可行性仅限于特定人群，这阻碍了市场扩张，儘管肿瘤疾病的发生率不断上升。

市场趋势

人工智慧 (AI) 在治疗方案选择中的应用正在革新兽医肿瘤学，将临床判断从经验通讯协定转向数据驱动的精准医疗。 AI 演算法分析活体癌细胞反应和流式细胞技术数据，在化疗给药前预测化疗，从而显着减少试验流程。这种功能性精准医疗方法使兽医能够根据每位患者独特的生物学特征优化治疗方案，提高缓解率并最大限度地减少不必要的毒性。 ImpriMed 于 2024 年 9 月宣布，其 AI 驱动平台已成功指导超过 7500 例犬猫血液癌症患者的治疗，证明了演算法决策支持在常规临床实践中的商业性扩充性。

同时，比较肿瘤学和「同一健康」模式正在加速新型治疗方法的研发，这些疗法充分利用了犬类自然发生的癌症与人类恶性肿瘤之间的生物学相似性。由于犬类肿瘤比囓齿动物异种移植模型更能有效预测人类药物反应，製药开发商正越来越多地将伴侣犬的临床试验纳入开发平臺，使伴侣动物能够更早获得前沿的人类治疗方法。这种双赢局面产生了高度精确的临床基因组资料集，推动了两个物种的创新。例如，2024年10月，FidoCure宣布其分析了508例伴侣犬患者的基因组数据，并确定了可直接指导犬类和人类血管肉瘤治疗策略的标靶治疗效果。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球宠物癌症药物市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依治疗方法（手术、放射线治疗、化疗、免疫疗法、其他）
  • 动物种类（狗、猫、其他）
  • 癌症类型（淋巴瘤、肥大细胞瘤、乳癌/鳞状细胞癌、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美宠物癌症药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲宠物癌症药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区宠物癌症药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲宠物癌症药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲宠物癌症药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球宠物癌症药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• CH Boehringer Sohn Ko. KG
• ELIAS Animal Health, LLC
• Zoetis Inc.
• AB Science SA
• Karyopharm Therapeutics, Inc.
• Vivesto AB
• Merial Inc.
• Elanco Animal Health, Inc.
• Dechra Pharmaceuticals PLC
• Torigen Pharmaceuticals Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Pet Cancer Therapeutics Market is projected to expand significantly, growing from USD 467.69 Million in 2025 to USD 816.41 Million by 2031, reflecting a 9.73% CAGR. This sector encompasses a specialized range of pharmaceutical and biologic agents, such as immunotherapies, chemotherapies, and targeted molecular drugs, all engineered to address malignancies in companion animals. The market's growth is primarily fueled by the increasing life expectancy of pets, which naturally leads to a higher prevalence of age-related cancers, and the strengthening human-animal bond that drives owners to seek veterinary oncology care comparable to human medical standards. Additionally, advancements in diagnostic precision allow for earlier tumor detection, creating an immediate demand for effective interventions beyond basic palliative care.

A major hurdle to broader market expansion is the high cost associated with advanced oncological regimens, which often restricts access for pet owners without insurance. Despite these financial barriers, overall investment in animal health continues to rise, highlighting the priority owners place on veterinary well-being. According to the American Pet Products Association, veterinary care and product sales in the United States reached $39.8 billion in 2024. This substantial expenditure demonstrates the strong economic foundation supporting the development and commercialization of new cancer therapies, even amidst the challenges posed by the high price points of these sophisticated treatments.

Market Driver

The landscape of the Global Pet Cancer Therapeutics Market is being transformed by the development of novel targeted therapies and immunotherapies, marking a significant shift away from traditional, non-specific chemotherapy. Veterinary oncology is increasingly adopting precision medicine approaches, utilizing monoclonal antibodies and autologous vaccines to enhance clinical outcomes while minimizing adverse effects. This transition towards efficacy-driven innovation is underscored by recent successes in immunotherapy, which provide compelling evidence to owners seeking life-extending options for their pets. for example, Torigen Pharmaceuticals reported in February 2025 that dogs with metastatic hemangiosarcoma treated with their targeted immunotherapy achieved a 3.5-fold increase in overall survival compared to surgery alone, a result that is accelerating the commercial adoption of these advanced agents.

Simultaneously, the expansion of pet health insurance coverage is acting as a crucial financial enabler, alleviating the economic barriers that historically limited access to premium oncological treatments. As insurance penetration deepens, pet owners are better equipped to afford expensive therapeutic regimens, converting latent demand into realized market revenue. The North American Pet Health Insurance Association reported in April 2025 that the total number of insured pets in North America reached 7.03 million at the end of 2024, representing a 12.2% annual increase. This growing financial safety net encourages pharmaceutical companies to invest heavily in their pipelines; for instance, Elanco Animal Health raised its 2025 innovation revenue target to between $660 million and $740 million in May 2025, highlighting the robust commercial potential of bringing next-generation veterinary therapeutics to market.

Market Challenge

The prohibitive cost of advanced oncological regimens presents a substantial barrier to the growth of the Global Pet Cancer Therapeutics Market. Although emerging targeted drugs and chemotherapies offer improved clinical outcomes, their high price points often render them inaccessible to a large segment of the pet-owning population. In the absence of widespread third-party reimbursement, the financial burden falls almost entirely on the pet owner, forcing many clients to forego curative treatment in favor of less expensive palliative options. This economic pressure constrains the addressable market for pharmaceutical developers and limits the return on investment for new drug development.

This constraint is intensified by the limited adoption of pet insurance, which leaves most owners vulnerable to sudden, high-cost medical expenses. According to the North American Pet Health Insurance Association, the total number of insured pets in the United States was 6.4 million in 2024, representing a market penetration rate of just 3.9%. Because the vast majority of companion animals lack coverage, the commercial viability of premium therapeutics is restricted to a narrow demographic, hampering broader market expansion despite the rising incidence of neoplastic diseases.

Market Trends

The application of Artificial Intelligence in treatment selection is revolutionizing veterinary oncology by shifting clinical decision-making from empirical protocols to data-driven precision. AI algorithms now analyze live tumor cell responses and flow cytometry data to predict the efficacy of specific chemotherapeutic agents before administration, significantly reducing trial-and-error in prescribing. This functional precision medicine approach allows veterinarians to tailor regimens to the unique biological profile of each patient, optimizing remission rates and minimizing unnecessary toxicity. According to ImpriMed in September 2024, the company's AI-driven platform had successfully guided treatment for over 7,500 canine and feline blood cancer patients, validating the commercial scalability of algorithmic decision support in routine practice.

Simultaneously, the leveraging of Comparative Oncology and One Health models is accelerating the development of novel therapeutics by utilizing the biological similarities between spontaneous canine cancers and human malignancies. Pharmaceutical developers are increasingly integrating pet dog clinical trials into their R&D pipelines, as canine tumors provide a more predictive model for human drug response than rodent xenografts, granting pets early access to cutting-edge human-grade therapies. This bi-directional benefit is generating high-fidelity clinico-genomic datasets that drive innovation across both species. For instance, FidoCure announced in October 2024 that it analyzed genomic data from 508 pet dog patients to identify targeted therapeutic outcomes that directly inform treatment strategies for both canine hemangiosarcoma and human angiosarcoma.

Key Market Players

• C.H. Boehringer Sohn Ko. KG
• ELIAS Animal Health, LLC
• Zoetis Inc.
• AB Science S.A.
• Karyopharm Therapeutics, Inc.
• Vivesto AB
• Merial Inc.
• Elanco Animal Health, Inc.
• Dechra Pharmaceuticals PLC
• Torigen Pharmaceuticals Inc

Report Scope

In this report, the Global Pet Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pet Cancer Therapeutics Market, By Therapy

• Surgery
• Radiotherapy
• Chemotherapy
• Immunotherapy
• Others

Pet Cancer Therapeutics Market, By Animal Type

• Canine
• Feline
• Others

Pet Cancer Therapeutics Market, By Cancer Type

• Lymphoma
• Mast Cell Cancer
• Mammary & Squamous Cell Cancer
• Others

Pet Cancer Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pet Cancer Therapeutics Market.

Available Customizations:

Global Pet Cancer Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pet Cancer Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy (Surgery, Radiotherapy, Chemotherapy, Immunotherapy, Others)
  • 5.2.2. By Animal Type (Canine, Feline, Others)
  • 5.2.3. By Cancer Type (Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell Cancer, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Pet Cancer Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy
  • 6.2.2. By Animal Type
  • 6.2.3. By Cancer Type
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pet Cancer Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy
      • 6.3.1.2.2. By Animal Type
      • 6.3.1.2.3. By Cancer Type
  • 6.3.2. Canada Pet Cancer Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy
      • 6.3.2.2.2. By Animal Type
      • 6.3.2.2.3. By Cancer Type
  • 6.3.3. Mexico Pet Cancer Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy
      • 6.3.3.2.2. By Animal Type
      • 6.3.3.2.3. By Cancer Type

7. Europe Pet Cancer Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy
  • 7.2.2. By Animal Type
  • 7.2.3. By Cancer Type
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pet Cancer Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy
      • 7.3.1.2.2. By Animal Type
      • 7.3.1.2.3. By Cancer Type
  • 7.3.2. France Pet Cancer Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy
      • 7.3.2.2.2. By Animal Type
      • 7.3.2.2.3. By Cancer Type
  • 7.3.3. United Kingdom Pet Cancer Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy
      • 7.3.3.2.2. By Animal Type
      • 7.3.3.2.3. By Cancer Type
  • 7.3.4. Italy Pet Cancer Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy
      • 7.3.4.2.2. By Animal Type
      • 7.3.4.2.3. By Cancer Type
  • 7.3.5. Spain Pet Cancer Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy
      • 7.3.5.2.2. By Animal Type
      • 7.3.5.2.3. By Cancer Type

8. Asia Pacific Pet Cancer Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy
  • 8.2.2. By Animal Type
  • 8.2.3. By Cancer Type
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pet Cancer Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy
      • 8.3.1.2.2. By Animal Type
      • 8.3.1.2.3. By Cancer Type
  • 8.3.2. India Pet Cancer Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy
      • 8.3.2.2.2. By Animal Type
      • 8.3.2.2.3. By Cancer Type
  • 8.3.3. Japan Pet Cancer Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy
      • 8.3.3.2.2. By Animal Type
      • 8.3.3.2.3. By Cancer Type
  • 8.3.4. South Korea Pet Cancer Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy
      • 8.3.4.2.2. By Animal Type
      • 8.3.4.2.3. By Cancer Type
  • 8.3.5. Australia Pet Cancer Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy
      • 8.3.5.2.2. By Animal Type
      • 8.3.5.2.3. By Cancer Type

9. Middle East & Africa Pet Cancer Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy
  • 9.2.2. By Animal Type
  • 9.2.3. By Cancer Type
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Pet Cancer Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy
      • 9.3.1.2.2. By Animal Type
      • 9.3.1.2.3. By Cancer Type
  • 9.3.2. UAE Pet Cancer Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy
      • 9.3.2.2.2. By Animal Type
      • 9.3.2.2.3. By Cancer Type
  • 9.3.3. South Africa Pet Cancer Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy
      • 9.3.3.2.2. By Animal Type
      • 9.3.3.2.3. By Cancer Type

10. South America Pet Cancer Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy
  • 10.2.2. By Animal Type
  • 10.2.3. By Cancer Type
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Pet Cancer Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy
      • 10.3.1.2.2. By Animal Type
      • 10.3.1.2.3. By Cancer Type
  • 10.3.2. Colombia Pet Cancer Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy
      • 10.3.2.2.2. By Animal Type
      • 10.3.2.2.3. By Cancer Type
  • 10.3.3. Argentina Pet Cancer Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy
      • 10.3.3.2.2. By Animal Type
      • 10.3.3.2.3. By Cancer Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Pet Cancer Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. C.H. Boehringer Sohn Ko. KG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. ELIAS Animal Health, LLC
• 15.3. Zoetis Inc.
• 15.4. AB Science S.A.
• 15.5. Karyopharm Therapeutics, Inc.
• 15.6. Vivesto AB
• 15.7. Merial Inc.
• 15.8. Elanco Animal Health, Inc.
• 15.9. Dechra Pharmaceuticals PLC
• 15.10. Torigen Pharmaceuticals Inc

16. Strategic Recommendations

17. About Us & Disclaimer